Efficacy of dupilumab application in bullous pemphigoid proceeding in presence of bronchial asthma

Karzanov OV, Baranov IA, Molochkov AV, Nikishenkov AM, Kabanova TG, Gureeva MA, Molochkova YuV. Efficacy of dupilumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Venereology. 2025;24(2):204‑209. (In Russ.)
https://doi.org/10.17116/klinderma202524021204

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Synergistic efficiency of preformed physical factors and dupilumab in the treatment of polypous rhinosinusitis. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(2):16-23

Relationship between oxidative stress patterns and proinflammatory cytokines in patients with polypous rhinosinusitis under the course of therapeutic physical factors. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(2):42-49

Prognostic factors for progression and risk chronic obstructive pulmonary disease adverse outcomes. Journal of Respiratory Medicine. 2025;(2):71-78

Laboratory considerations in assessing efficacy and safety of biologic therapy in the elderly (as Exemplified by Asthma). Laboratory Service. 2025;(2):29-32

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;(4):96-104

Mechanisms of additivity of physiotherapeutic factors in complex therapy of polypous rhinosinusitis complicated by comorbidities. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(3):5-11

Influence of age and sex on values of SNOT-22 sinonasal test domains in children and adolescents with bronchial asthma. Russian Rhinology. 2025;(3):197-204

Features of depressive disorders and suicidal behavior in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):7-13

Results of an open-label, randomized, multicenter, comparative study of clinical efficacy and safety of Pulmibud drug and Pulmicort drug in patients with partially controlled and uncontrolled persistent bronchial asthma. Journal of Respiratory Medicine. 2025;(3):33-38

Current status of impulse oscillometry in pulmonary practice. Journal of Respiratory Medicine. 2025;(3):65-71

Abstract:

Bullous pemphigoid is an autoimmune skin disease more commonly seen in elderly people. The disease was for the first time described in 1953 by W. F. Lever. It is characterized by the appearance of subepidermal vesicles caused by the formation of IgG-autoantibodies to the components of hemidesmosomes (BP180 (BPAg2) and BP230 (BPAg1) antigens) in the area of basal membrane of the skin, that may be related to various factors, including drug induction. Conventional treatment with systemic glucocorticosteroids, despite its sufficiently high efficacy, is often complicated taking into account the high probability of patients’ somatic burden, that makes it necessary to find and apply innovative treatment methods. Current studies demonstrate the significant role of type 2 inflammation (Th-2 inflammation) in the pathogenesis of bullous pemphigoid, that opens new possibilities for the application of genetically engineered biological agents for exposure to potential therapeutic targets. We present the clinical observation of a subject suffering from bullous pemphigoid, severe atopic bronchial asthma and receiving dupilumab with pronounced positive dynamics. The possibility of using targeted therapy in bullous pemphigoid sufferers, which allows to provide the best prognosis for patients with somatic complications is discussed.

Keywords:

bullous pemphigoid

dupilumab

comorbidity

bronchial asthma

Authors:

Karzanov O.V.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

ORCID: 0000-0002-2461-546X

Baranov I.A.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

ORCID: 0009-0006-1225-0420

Molochkov A.V.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

ORCID: 0000-0002-6456-998X

Nikishenkov A.M.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

ORCID: 0000-0002-2133-8428

Kabanova T.G.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

ORCID: 0000-0002-8667-9506

Gureeva M.A.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

ORCID: 0000-0001-8212-6210

Molochkova Yu.V.

M.F. Vladimirsky Moscow Regional Research and Clinical Institute

ORCID: 0000-0001-9021-6494

Received:

12.03.2024

Accepted:

16.01.2025

Close metadata

References:

Persson MSM, Begum N, Grainge MJ, Harman KE, Grindlay D, Gran S. The global incidence of bullous pemphigoid: A systematic review and meta-analysis. Br J Dermatol. 2022;186(3):414-425. https://doi.org/10.1111/bjd.20743
Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Bullous pemphigoid. Autoimmun Rev. 2017;16(5):445-455. https://doi.org/10.1016/j.autrev.2017.03.010
Zhang L, Chen Z, Wang L, Luo X. Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol. 2023 Feb 16;14:1115083. PMID: 36875098; PMCID: PMC9978795. https://doi.org/10.3389/fimmu.2023.1115083
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: A systematic literature review. Clin Ther. 2017; 39(11):2216-2229. https://doi.org/10.1016/j.clinthera.2017.09.011
Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18(5):526-534. https://doi.org/10.1016/j.autrev.2019.03.009
Ameglio F, D’Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: Relationships with disease intensity. Br J Dermatol. 1998;138(4):611-614. https://doi.org/10.1046/j.1365-2133.1998.02169.x
D’Auria L, Pietravalle M, Mastroianni A, Ferraro C, Mussi A, Bonifati C, et al.. Il-5 levels in the serum and blister fluid of patients with bullous pemphigoid: Correlations with eosinophil cationic protein, rantes, ige and disease severity. Arch Dermatol Res. 1998;290(1-2):25-27. https://doi.org/10.1007/s004030050272
Pickford WJ, Gudi V, Haggart AM, Lewis BJ, Herriot R, Barker RN, et al. T Cell participation in autoreactivity to Nc16a epitopes in bullous pemphigoid. Clin Exp Immunol. 2015;180(2):189-200. https://doi.org/10.1111/cei.12566
Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T Cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5-17. https://doi.org/10.1016/j.cyto.2014.09.011
Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Dupiksent (dupilumab) ot 17 iyulya 2020 g. Registratsionnyj nomer LP-005440. (In Russ.).
Molochkova YuV, Karzanov OV, Molochkov VA, Monayenkova MK. Dupilumab in dermatology: atopic dermatitis and promising directions. Effektivnaya farmakoterapiya. 2022;18(9):18-23. (In Russ.).
Nenasheva NM. Long-term safety and efficacy of dupilumab in patients with moderate to severe asthma. Practical Allergology. 2021;2:66-78. (In Russ.). https://doi.org/10.46393/2712-9667_2021_2_66_78
Abdat R, Waldman RA, de Bedout V, Czernik A, McLeod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. J Am Acad Dermatol. 2020;83(1):46-52. https://doi.org/10.1016/j.jaad.2020.01.089
Takamura S, Teraki Y. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines. J Dermatol. 2022;49(9):845-850. https://doi.org/10.1111/1346-8138.16428
Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, Amagai M, Bauer J, Beissert S, Borradori L, Culton D, Fairley JA, Fivenson D, Jonkman MF, Marinkovich MP, Woodley D, Zone J, Aoki V, Bernard P, et al. Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology. 2015;72(1):168-174. https://doi.org/10.1016/j.jaad.2014.08.024
Pfütze M, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007 Jan-Feb;17(1):4-11. Epub 2007 Feb 27. PMID: 17324820. https://doi.org/10.1684/ejd.2007.0090

Bernier A, Rumyantseva T, Reques L, Volkova N, Kyburz Y, Maximov O, Derrienic E, Guschin A, Bouscaillou J, Luhmann N, Pataut D. HIV and other sexually transmitted infections among female sex workers in Moscow (Russia): prevalence and associated risk factors. Sex Transm Infect. 2020 Dec;96(8):601-607. https://doi.org/10.1136/sextrans-2019-054299

Shipitsyna E, Khusnutdinova T, Budilovskaya O, et al. Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia. Eur J Clin Microbiol Infect Dis. 2020;39(7):1221-1230. https://doi.org/10.1007/s10096-020-03831-w